Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 572

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 4
Chunk 572
---
, 2024, we earned $42,000 for advisory and related services which is recorded in other income in the accompanying consolidated
statement of operations.

     F-24 

    Mosaic ImmunoEngineering, Inc.

    Notes to Consolidated Financial Statements
    For the Years Ended December 31, 2024 and 2023 (continued)

14. Segment Information

The Company manages its operations as a single operating
segment for the purposes of assessing performance and making operating decisions. The Company’s primary focus is on research and development
of immunotherapies with broad potential to treat cancer. The determination of a single business segment is consistent with the consolidated
financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s
CODM is its President and Chief Executive Officer, who reviews and evaluates consolidated net loss for purposes of making operating decisions.

15. Subsequent Events

We have evaluated subsequent events after the consolidated
balance sheet date and through the filing date of this Report, and based on our evaluation, management has determined that no other subsequent
events have occurred that would require recognition in the accompanying consolidated financial statements or disclosure in the notes thereto
other than as disclosed herein and in the accompanying notes.

 F-25